Antiplatelet effects of aspirin and clopidogrel after left atrial appendage (LAA) occluder implantation
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in International Journal of Cardiology
- Vol. 275, 95-100
Abstract
No abstract availableKeywords
Funding Information
- Heinrich-Heine-Universität Düsseldorf (46-2016)
- Heinrich-Heine-Universität Düsseldorf (16-2014)
- Heinrich-Heine-Universität Düsseldorf (32-2018)
This publication has 48 references indexed in Scilit:
- Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapyInternational Journal of Cardiology, 2013
- CYP2C19*2 and other genetic variants affecting platelet response to clopidogrel in patients undergoing percutaneous coronary interventionThrombosis Research, 2012
- Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary InterventionCirculation, 2011
- Consensus and Future Directions on the Definition of High On-Treatment Platelet Reactivity to Adenosine DiphosphateJACC, 2010
- Intra-individual variability in clopidogrel responsiveness in coronary artery disease patients under long term therapyPlatelets, 2010
- Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trialThe Lancet, 2009
- Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysisBMJ, 2008
- Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial FibrillationCirculation, 2007
- Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 scoreThrombosis Research, 2007
- The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) TrialAmerican Heart Journal, 2006